Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree bio. Unfortunately, there are very likely many who would prefer to see this up and coming bio fail. No more need for insulin and tumor remission are just a couple of reasons.
I am holding long here after much DD. I know what I own.
http://www.pharmacytebiotech.com/media/
The article was published 10 years ago. Dr Lohr and the other doctors involved in the study shared the results at that time. The good doctor did not sit on anything. These doctors are very interested in getting Cell in a Box to patients. I believe we are on course to make that happen. BTW, this company did not get exclusive rights to this technology for cancer until 2013. And a few months later, Ken Waggoner joined us and a few months after that, so did Dr Von Hoff. Things have been progressing very well since our new additions.
http://www.nature.com/cgt/journal/v13/n1/full/7700849a.html
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
Great article Pete!
That is nice to hear. Thanks for sharing...
Very nice post, Rudy.
NewsWatch PMCB video segment.
I watched it a few times and each time I was more and impressed how so much info got into just a few minutes. This is a whole new forum for us.
GLTA
http://newswatchblog.com/2015/07/01/live-cell-encapsulation/
I think Dr Lohr addressed the fact that technology has advanced a lot since 2007 in the corporate video. He said they are able to do much more than in the past with all the new technological advancements. However, we are all anxious to hear that we have GMP approval. And that includes our CEO as he forthrightly mentioned in the Q&A. No one is walking around with blinders on. We understand the business and the challenges. Thanks for your well wishes.
4. The initiation of these three clinical trials is dependent on the approval for use of the Cell-in-a-Box® live cell encapsulation facility that has been constructed in Bangkok, Thailand, by our partner, Austrianova. This facility must be approved as being compliant with current Good Manufacturing Practices (cGMP) standards by Thailand’s and Australia’s drug regulatory authorities as well as by the U.S. FDA.
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
I see no reason to question a CEOs statement about quarterly events. It is not an assumption about what is meant by quarterly, it is well understood by almost everyone. I shared the investopia link. I don't think it is the CEO trying to confuse people. Third quarter is understood by the majority of the population and by everyone with any business experience...
Furthermore, this Q&A was done May 2015. The question posed is for 2015. So it is clear we are talking 3q/15.
Q: What other milestones do you hope to accomplish in 2015?
The major milestones for the remainder of 2015 are:
1. Complete the population of our Board of Directors with individuals who have extensive experience in life sciences and who have associated business expertise.
- Fully populate our Scientific Advisory Board with world-class physicians and scientists experienced in the fields of cancer and diabetes.
- Initiation of the Phase 2b clinical trial in Australia in patients with advanced pancreatic cancer. This is expected to begin in late 3Q2015.
2. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment dealing with pain associated with advanced pancreatic cancer. This trial, to be conducted in the U.S., is expected to begin in late 3Q2015.
3. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment in slowing the accumulation of malignant ascites fluid. This trial, to also be conducted in the U.S., is expected to occur in late 3Q2015 or early 4Q2015.
4. The initiation of these three clinical trials is dependent on the approval for use of the Cell-in-a-Box® live cell encapsulation facility that has been constructed in Bangkok, Thailand, by our partner, Austrianova. This facility must be approved as being compliant with current Good Manufacturing Practices (cGMP) standards by Thailand’s and Australia’s drug regulatory authorities as well as by the U.S. FDA.
5. Completion of our laboratory and small animal studies with the Melligen cells that are necessary to develop our treatment for insulin-dependent diabetes. These studies are designed to obtain data that will be required by regulatory authorities before any human clinical trials can occur.
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
I think he is thinking the same thing as all CEOs. They all follow the same quarterly calendar. Not only do we have this as a plan item but so does TD2 (our CRO). TD2 will be conducting the trials. This is a joint plan. I am not anticipating any delays and have no reason to suspect any.
This should clear things up. Explains right here what are the months related to each quarter. And, regardless of when a company's 10q's and 10K are due, the dates related to the definition of quarters 1-4 does not change.
Quarter - Q1, Q2, Q3, Q4
DEFINITION OF 'QUARTER - Q1, Q2, Q3, Q4'
A three-month period on a financial calendar that acts as a basis for the reporting of earnings and the paying of dividends. A quarter refers to one-fourth of a year and is typically expressed as "Q." The four quarters that make up the year are: January, February and March (Q1); April, May and June (Q2); July, August and September (Q3); and October, November and December (Q4). A quarter is often shown with its relevant year, as in Q1 2012 or Q1/12, which represents the first quarter of the year 2012.
INVESTOPEDIA EXPLAINS 'QUARTER - Q1, Q2, Q3, Q4'
All public companies in the United States must file quarterly reports (known as 10-Qs) with the U.S. Securities and Exchange Commission (SEC). Each 10-Q contains the public company's unaudited financial statements and company operations information for the previous three months (quarter). 10-Qs are required for the first three quarters of the year. Each publicly traded company must also file an annual report, known as a 10-K, which includes all of the quarters.
Companies, investors and analysts use data from different quarters to make comparisons and evaluate trends. For instance, a retailer may compare this year's Q2 sales over last year's Q2 sales, or an analyst may evaluate a firm's earnings by reviewing data from the same quarter over several years.
Read more: http://www.investopedia.com/terms/q/quarter.asp#ixzz3ef0T5fF5
Follow us: @Investopedia on Twitter
Just imagine if Apple said they were releasing a product in the fourth quarter and the public expected it between October and December but... But, Oh no! They meant their fiscal quarter which is... When? Absolutely ludicrous to expect a company to make a public announcement for a company venture and have the timeline related to their fiscal year. Just a ridiculous argument. And in fact, trials will start at the end of the 3rd quarter.
Short positions love the fact that bios take time. Urgency can be created as a result. However, longs must know this so they do not to fall into this hurry, hurry, rush, rush trap.
PharmaCyte Biotech Enters Into Research & Consulting Agreement
6/29/2015
PharmaCyte Biotech, Inc. recently announced it has signed a major Research Services Agreement and an important Consulting Contract with the University of Technology Sydney (UTS) in Australia. Both of these contracts concern the development of PharmaCyte Biotech’s treatment for insulin-dependent diabetes that is composed of proprietary human non-pancreatic insulin-producing cells (Melligen cells) that are to be encapsulated using its cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
The Research Services Agreement is designed to provide funding to UTS that will permit Prof. Ann Simpson, the world’s foremost authority on the Melligen cells, and her colleagues at UTS to conduct pivotal studies with Melligen cells in order to help fully characterize the parameters by which these cells produce insulin “on demand” when they are encapsulated using the Cell-in-a-Box technology. The Consulting Contract will allow Prof. Simpson to devote a sufficient amount of her time to working with PharmaCyte Biotech and its international Diabetes Consortium as it pursues the development of its diabetes treatment for insulin dependent diabetes.
“Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer, commented “The Research Services Agreement and Prof. Simpson’s Consulting Contract are extremely important and very necessary as PharmaCyte Biotech pursues its goal of developing a treatment for insulin-dependent diabetes. We are particularly pleased that Prof. Simpson has agreed to join us as a consultant because, not only was she a founding member of our Diabetes Consortium, her expertise in dealing with the Melligen cells will undoubtedly continue to be indispensable as we move forward in our efforts to find an effective treatment for all those who are in need of insulin to live a normal life.”
PharmaCyte Biotech is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known chemotherapy prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working toward improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
For more information, visit www.pharmacyte.com.
- See more at: http://www.drug-dev.com/Main/Current-News/PharmaCyte-Biotech-Enters-Into-Research-Consulting-1362.aspx#sthash.75CnYW18.dpuf
Agree 100% with everything you said.
Can you imagine if every business followed their financial quarters when discussing plan items? We would all be so confused. It would be ridiculous. So when a company mentions quarterly plans to the public, it's based on the calendar year. Otherwise, for every company PR, we'd need to have a copy of the company's financials to figure out when is their fiscal quarter. Just counterintuitive...
Absolutely Rudy. We wait, patiently... I have learned a lot about waiting. It's what you do when own a biotech. But I believe it will be well worth the wait. I am excited to one day be a part of human trials...
TD2 focuses on getting drugs to patients more quickly. This interview with Dr Von Hoff provides insight into his trial designs. After reading this, I understand why they are ensuring they have all the right parameters in preclinicals. It's a good article.
http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/
Thanks for providing details of plan items for the year. I agree this is a long term hold here. Here are notes from the Q&A with Ken Waggoner as well.
Q: What other milestones do you hope to accomplish in 2015?
The major milestones for the remainder of 2015 are:
1. Complete the population of our Board of Directors with individuals who have extensive experience in life sciences and who have associated business expertise.
- Fully populate our Scientific Advisory Board with world-class physicians and scientists experienced in the fields of cancer and diabetes.
- Initiation of the Phase 2b clinical trial in Australia in patients with advanced pancreatic cancer. This is expected to begin in late 3Q2015.
2. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment dealing with pain associated with advanced pancreatic cancer. This trial, to be conducted in the U.S., is expected to begin in late 3Q2015.
3. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment in slowing the accumulation of malignant ascites fluid. This trial, to also be conducted in the U.S., is expected to occur in late 3Q2015 or early 4Q2015.
4. The initiation of these three clinical trials is dependent on the approval for use of the Cell-in-a-Box® live cell encapsulation facility that has been constructed in Bangkok, Thailand, by our partner, Austrianova. This facility must be approved as being compliant with current Good Manufacturing Practices (cGMP) standards by Thailand’s and Australia’s drug regulatory authorities as well as by the U.S. FDA.
5. Completion of our laboratory and small animal studies with the Melligen cells that are necessary to develop our treatment for insulin-dependent diabetes. These studies are designed to obtain data that will be required by regulatory authorities before any human clinical trials can occur.
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
Happens everyday. Longs are no longer surprised when we hear this. We are not as easily shaken but that is because we believe in the technology and know what we own. :)
Good luck to you...
Trently, I don't play the guessing game. I know what next steps there are, so I just wait for the news from the company. It seems there is a lot going on behind the scenes. The fact that our management teams appears to be doing all the right things is enough to give me peace of mind that my money is just sitting in the bank, waiting to pop when those milestones are achieved one by one.
Great point. A lot of attention is being drawn to this company. There is evidently a reason. Longs do know that reason, Cell in a Box technology. It can be seen as a threat to some and a saving grace to others. Either way, it garners attention because of its potential to revolutionize the medical industry. It is just not human nature to give a thought to something for which one has no interest. Just doesn't happen, not at averaging over 2 million shares traded daily...
Yes,sir, to each his own... And I said it was noteworthy...
Any Institutional Interest in a penny stock is noteworthy, IMO. Why would they purchase any shares if it were not to watch the progress being made. Maybe they will be watching the Discovery channel tomorrow. Better chance they will than they won't since they have us on their watch list. :)
A man of few words that say a heck of a lot! Yes, we have "structured a great team to push thru FDA".
Great point jz... Many will see this video who don't follow penny stocks. And the Discovery Channel is all about sharing valuable information and attracts bright innovative minds. And, they contacted PMCB for the story. Amazing Good Stuff!
PharmaCyte Biotech’s Cancer and Diabetes Treatments Airing Nationwide on Discovery Channe
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its technology and treatments will be featured on the Discovery Channel and ION Network tomorrow morning, June 30, 2015, from 7:00-7:30 a.m. EDT and PDT, except on DISH Network which airs using the EDT time zone. PharmaCyte Biotech’s story will air on Discovery Channel and ION Network’s news magazine series “NewsWatch,” a source for breaking consumer, technology, travel, health and entertainment news since 1990.
NewsWatch, based in the Washington, DC area, airs nationwide in the U.S. and can be seen in virtually every market throughout the country. Each edition of NewsWatch reaches more than 96 million U.S. households. Over 700 million people have viewed the NewsWatch series, making it one of the most successful independently produced news magazines on television. NewsWatch will present PharmaCyte Biotech’s story in “HealthWatch,” a segment that provides viewers with the latest medical breakthroughs and newest medical advances that can improve their health.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We have a great story, and when we were contacted by NewsWatch to present our technology and the targeted treatments we’re developing for cancer and diabetes to their nationwide audience, we jumped at the opportunity. Our mission is about helping people. We can think of no better way to connect with people than to have our compelling story air on the Discovery Channel and ION Network and potentially be seen by the 96 million households they reach in the U.S.”
Since the series began in 1990, NewsWatch has featured more than 10,000 individual stories on a wide range of subjects, including medical breakthroughs, finance, travel, new product introductions, public policy issues, entertainment, celebrities and numerous other topics.
Name change to focus on current Biotech business model.
http://globenewswire.com/news-release/2015/01/07/695650/10114423/en/Nuvilex-Announces-Name-Change-to-PharmaCyte-Biotech.html
Got lots of folks looking forward to this technology, type 1 diabetics, pancreatic cancer patients, cancer patients with malignant ascites... Just to name a few.
Kind of hurts efforts to improve the lives of folks when shorts need to cover.
If you know what I mean...
What's the magic number?
When would be a good time to cover?
:)
PMCB
I agree. It's a risk for sure but we do have some heavy hitting doctors and scientists involved. We should make it far enough to get to the point where we gain interest from big money. I imagine some would like to see us fail. But Good-willed efforts can be victorious. I will persevere. I can afford to withstand all the hits. I have my priorities and, I understand the risks I take by sticking with them. Fast Easy Money is not to be found here. It is a long slow grind but well worth the risk and wait, IMO.
I like your new tag Bill. Stand for something or fall for anything. "BIG DAWG". :)
I completely support Cell in a Box(R) technology!
I agree Bio. That document was written almost a year ago. If there was anything out of the ordinary going on, we would know that by now...
My investment is working out just fine. Cell in a Box(R) technology is on course to prove its worth. It takes time as biotech's have a lengthy process to get from R&D to patients.
And I agree with you, in the meantime, we are an easy target. So while we wait for FDA, there will be volatility.
I do not concern myself with anything other than our efforts to get this to market. I do my DD and look at all opinions. Nothing trumps Cell in a Box(R) technology. That is just my opinion but I will be holding still when all the dust does settle.
Hi, Bill. Cell in a Box(R) technology stands on its own merits. I do not concern myself anymore with all the negative attention because it is so transparent what is going on. And biotech's take so long to get from one step to the next which makes them an easy target. I believe so strongly in this technology and this team that I am willing to endure the volatility and barrage of attacks.
You have to do your DD and decide if you want to support the company's efforts to make a difference in so many lives. Dr Von Hoff saw something in the technology and with his extensive experience working for and with the FDA, I am confident we will prevail...
It all sounds so familiar...
I am sure shares will change hands until we are past our R&D phase. However, there are some who see this investment as it should be viewed, long term. So, not everyone is selling and I think some who sell today may regret that decision in the future. As long as we continue our path to bring this product to patients, I am holding long and firm, will not be able to shake shares from my hand. I have done my homework and I know the potential here.
:)
Biotech in R & D. This is a long term hold. Long term gains will be well worth the hold as a Diabetes alone is worth billions. However, expecting big gains in the short term will disappoint. Lots of volatility without major news and I expect that will not come until trials are underway. That's just my opinion and who knows, a partnership or buy out could possibly happen before then. Not a good idea to be in this one without believing in the technology and being willing to hold long term,
We are still in research and development.
'Cell-in-a-Box’ Diabetes treatment enters new phase, UTS to do research now
June 24, 2015
PharmaCyte Biotech, a clinical stage biotechnology company has announced that its new cancer and diabetes treatment method using live-cell encapsulation technology, Cell-in-a-Box, will be taken up by the University of Technology Sydney (UTS) in Australia.
Announcing its contract with the varsity, PharmaCyte Biotech said it will provide funding for the study on treatment of insulin-dependent diabetes that is comprised of proprietary human non-pancreatic insulin-producing cells (Melligen cells) to be encapsulated using its cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
The Research Services Agreement is designed to provide funding to UTS that will permit Prof. Ann Simpson, the world’s foremost authority on the Melligen cells, and her colleagues at UTS to conduct pivotal studies with Melligen cells in order to help fully characterize the parameters by which these cells produce insulin “on demand” when they are encapsulated using the Cell-in-a-Box technology.
The Consulting Contract will allow Prof. Simpson to devote a sufficient amount of her time to working with PharmaCyte Biotech and its international Diabetes Consortium as it pursues the development of its diabetes treatment for insulin dependent diabetes.
“Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer, commented, “The Research Services Agreement and Prof. Simpson’s Consulting Contract are extremely important and very necessary as PharmaCyte Biotech pursues its goal of developing a treatment for insulin-dependent diabetes.”
Prof. Simpson will be a consultant as she is also a founding member of PharmaCyte’s Diabetes Consortium, with expertise in dealing with the Melligen cells.
http://www.microfinancemonitor.com/cell-in-a-box-diabetes-treatment-enters-new-phase-uts-to-do-research-now/34419
There is definitely some mystery around this whole "funding" for her work. Sounds as if she will be focused on working with the consortium and very involved in clinical studies and trials. To get her to make that kind of commitment, there has to be some benefits to her and UTS. And knowing how valuable a cure is for diabetes, I would imagine there are those who would want to help fund our efforts. So much appears to be going on behind the scenes, I am feeling very good about all of our efforts.
A "sugar daddy"? Certainly a possibility. :)